The engineered exosomes (AD-MSC-Exo-199a) significantly enhanced the chemosensitivity of HCC cells by targeting the mTOR pathway, improving the delivery efficiency of adriamycin (Dox) to HCC cells, and demonstrating therapeutic efficacy in vivo [132]. This evidence concerns the gene MTOR and hepatocellular carcinoma.